Reuters
26 Aug 2026, 06:56 UTC · 8w ago
Impact · against what's priced in
Biohaven receives a significant valuation boost and non-dilutive funding through a licensing deal with SK Biopharmaceuticals worth up to $795 million. SK Biopharmaceuticals gains a strategic expansion of its epilepsy pipeline, providing a positive but smaller catalyst for its valuation.
No priced-in read yet
What the story claims
1 claim · scored −1 bearish … +1 bullish
Biohaven entered a licensing agreement with SK Biopharmaceuticals for its epilepsy drug platform, including Opakalim, for up to $795 million.
So whatSignificant non-dilutive funding and validation of the drug platform provide a substantial boost to Biohaven's balance sheet and valuation.
More positive than 94% of claims this week
Which stocks this story touches
Continue reading
5 related stories
The agreement for the epilepsy drug platform, including Opakalim, provides up to $795 million in potential funding and validates the company's drug platform.
Read from the article alone
No priced-in read yet
SK Biopharmaceuticals expands its drug pipeline through the strategic licensing of Biohaven's epilepsy platform.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 90% of ticker scores this week
Secured a licensing agreement potentially worth up to $795 million for its epilepsy drug platform.
More positive than 62% of ticker scores this week
Expanded its drug pipeline through a strategic licensing agreement for an epilepsy drug platform.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
2h ago
—
No price for 302440.KS right now — the quote feed didn't answer.
302440.KS chart →−18.3%
Price is moving against the score
$11.75 vs $14.38 close before publication (Aug 25) · not market-adjusted
BHVN chart →
